1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
Huang, K.
Xu, B.
Hu, S.Q.
Chu, Y.C.
Hua, Q.X.
Whittaker, J.
Nakagawa, S.H.
De Meyts, P.
Katsoyannis, P.G.
Weiss, M.A.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
C4 H9 N O2
103.120
n
ALPHA-AMINOBUTYRIC ACID
L-peptide linking
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C4 H7 N O4
133.103
y
ASPARTIC ACID
L-peptide linking
C3 H7 N O2 S
121.158
y
CYSTEINE
L-peptide linking
C5 H10 N2 O3
146.144
y
GLUTAMINE
L-peptide linking
C5 H9 N O4
147.129
y
GLUTAMIC ACID
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H10 N3 O2 1
156.162
y
HISTIDINE
L-peptide linking
C6 H13 N O2
131.173
y
ISOLEUCINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C6 H15 N2 O2 1
147.195
y
LYSINE
L-peptide linking
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C5 H9 N O2
115.130
y
PROLINE
L-peptide linking
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
C4 H9 N O3
119.119
y
THREONINE
L-peptide linking
C9 H11 N O3
181.189
y
TYROSINE
L-peptide linking
C5 H11 N O2
117.146
y
VALINE
L-peptide linking
UK
J.Mol.Biol.
JMOBAK
0070
0022-2836
341
529
550
10.1016/j.jmb.2004.05.023
15276842
How Insulin Binds: the B-Chain alpha-Helix Contacts the L1 beta-Helix of the Insulin Receptor.
2004
US
Biochemistry
BICHAW
0033
0006-2960
39
15826
15835
10.1021/bi001802+
11123908
MUTATIONAL ANALYSIS OF INVARIANT VALINE B12 IN INSULIN: IMPLICATION FOR RECEPTOR BINDING
2000
US
J.Biol.Chem.
JBCHA3
0071
0021-9258
272
12978
12983
10.1074/jbc.272.20.12978
9148904
ALANINE SCANNING MUTAGENESIS OF INSULIN
1997
AT
BIOCHEM.MOL.BIOL.INT.
BMBIES
2062
1039-9712
39
1245
1254
8876979
STUDIES ON RECEPTOR BINDING SITE OF INSULIN: THE HYDROPHOBIC B12VALCAN BE SUBSTITUTED BY HYDROPHILIC THR
1996
US
Biochemistry
BICHAW
0033
0006-2960
32
2631
2635
8448120
STERIC REQUIRMENTS AT POSITION B12 FOR HIGH BIOLOGICAL ACTIVITY IN INSULIN
1993
DK
INT.J.PEPT.PROTEIN RES.
IJPPC3
0215
0367-8377
17
243
255
7014485
[12-ASPARAGINE-B] HUMAN INSULIN. AN ANALOGUE WITH MODIFICATION IN THEHYDROPHOBIC CORE OF INSULIN
1981
10.2210/pdb1t1q/pdb
pdb_00001t1q
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
1
SINGLE WAVELENGTH
M
x-ray
1
1.0
2383.698
insulin
INSULIN A CHAIN
HIS-B10-ASP, VAL-B12-ABA, PRO-B28-LYS, LYS-B29-PRO
1
syn
polymer
3396.868
Insulin
INSULIN B CHAIN
1
syn
polymer
no
no
GIVEQCCTSICSLYQLENYCN
GIVEQCCTSICSLYQLENYCN
A
polypeptide(L)
no
yes
FVNQHLCGSDL(ABA)EALYLVCGERGFFYTKPT
FVNQHLCGSDLAEALYLVCGERGFFYTKPT
B
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
database_2
struct_conn
struct_ref_seq_dif
repository
Initial release
Version format compliance
Version format compliance
Database references
Database references
Derived calculations
1
0
2004-08-10
1
1
2008-04-30
1
2
2011-07-13
1
3
2012-03-28
1
4
2021-10-27
_database_2.pdbx_DOI
_database_2.pdbx_database_accession
_struct_conn.pdbx_leaving_atom_flag
_struct_ref_seq_dif.details
PARENT MOLECULE OF THIS DEPOSITION, CONTAINS THREE SUBSTITUTIONS
ALA-B12-DKP-INSULIN
THR-B12-DKP-INSULIN
RCSB
Y
RCSB
2004-04-16
REL
REL
THE PEPTIDE WAS CHEMICALLY SYNTHESIZED. THE SEQUENCE OF THE PEPTIDE IS NATURALLY FOUND IN HOMO SAPIENS(HUMAN)
sample
THE PEPTIDE WAS CHEMICALLY SYNTHESIZED. THE SEQUENCE OF THE PEPTIDE IS NATURALLY FOUND IN HOMO SAPIENS(HUMAN)
sample
This structure was determined by using standard 2D homonuclear techniques
structures with the lowest energy
50
15
2D NOESY
2D TOCSY
DQF-COSY
7.0
ambient
298
K
7.6
ambient
305
K
the structures are based on a total of 590 restraints: 527 are NOE-derived distance constraints, 39 are dihedral angle restraints, 24 are hydrogen bond restraints.
DISTANCE GEOMETRY AND SIMULATED ANNEALING
1
closest to the average
1.2 mM ABA-B12-DKP-insulin, 90% H2O, 10% D2O
90% H2O/10% D2O
1.2 mM ABA-B12-DKP-insulin,100% D2O
100% D2O
Molecular Simulations INC.
structure solution
DGII
INSIGHTII 2000
Brunger
refinement
X-PLOR
3.85
600
Varian
INOVA
800
Bruker
DRX
GLY
1
n
1
GLY
1
A
ILE
2
n
2
ILE
2
A
VAL
3
n
3
VAL
3
A
GLU
4
n
4
GLU
4
A
GLN
5
n
5
GLN
5
A
CYS
6
n
6
CYS
6
A
CYS
7
n
7
CYS
7
A
THR
8
n
8
THR
8
A
SER
9
n
9
SER
9
A
ILE
10
n
10
ILE
10
A
CYS
11
n
11
CYS
11
A
SER
12
n
12
SER
12
A
LEU
13
n
13
LEU
13
A
TYR
14
n
14
TYR
14
A
GLN
15
n
15
GLN
15
A
LEU
16
n
16
LEU
16
A
GLU
17
n
17
GLU
17
A
ASN
18
n
18
ASN
18
A
TYR
19
n
19
TYR
19
A
CYS
20
n
20
CYS
20
A
ASN
21
n
21
ASN
21
A
PHE
1
n
1
PHE
1
B
VAL
2
n
2
VAL
2
B
ASN
3
n
3
ASN
3
B
GLN
4
n
4
GLN
4
B
HIS
5
n
5
HIS
5
B
LEU
6
n
6
LEU
6
B
CYS
7
n
7
CYS
7
B
GLY
8
n
8
GLY
8
B
SER
9
n
9
SER
9
B
ASP
10
n
10
ASP
10
B
LEU
11
n
11
LEU
11
B
ABA
12
n
12
ABA
12
B
GLU
13
n
13
GLU
13
B
ALA
14
n
14
ALA
14
B
LEU
15
n
15
LEU
15
B
TYR
16
n
16
TYR
16
B
LEU
17
n
17
LEU
17
B
VAL
18
n
18
VAL
18
B
CYS
19
n
19
CYS
19
B
GLY
20
n
20
GLY
20
B
GLU
21
n
21
GLU
21
B
ARG
22
n
22
ARG
22
B
GLY
23
n
23
GLY
23
B
PHE
24
n
24
PHE
24
B
PHE
25
n
25
PHE
25
B
TYR
26
n
26
TYR
26
B
THR
27
n
27
THR
27
B
LYS
28
n
28
LYS
28
B
PRO
29
n
29
PRO
29
B
THR
30
n
30
THR
30
B
author_defined_assembly
2
dimeric
B
ABA
12
ALPHA-AMINOBUTYRIC ACID
B
ABA
12
ALA
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
x,y,z
identity operation
0.0000000000
0.0000000000
0.0000000000
1
A
B
H
O
ASN
GLY
21
23
1.48
1
B
B
O
H
GLY
LEU
8
11
1.49
1
B
B
O
H
GLU
LEU
13
17
1.50
2
A
B
H
O
ASN
GLY
21
23
1.46
2
B
B
O
H
GLY
LEU
8
11
1.47
2
B
B
O
H
CYS
GLU
19
21
1.58
3
A
B
H
O
ASN
GLY
21
23
1.44
3
B
B
O
H
GLU
LEU
13
17
1.52
4
A
B
H
O
ASN
GLY
21
23
1.49
4
A
A
O
H
GLN
SER
5
9
1.56
4
B
B
O
H
GLU
LEU
13
17
1.59
5
A
A
O
H
SER
GLN
12
15
1.58
6
A
B
H
O
ASN
GLY
21
23
1.47
6
B
B
O
H
ALA
VAL
14
18
1.51
6
B
B
O
H
GLU
LEU
13
17
1.59
7
A
B
H
O
ASN
GLY
21
23
1.48
7
B
B
O
H
GLU
LEU
13
17
1.50
7
B
B
O
H
GLY
LEU
8
11
1.56
8
B
B
O
H
GLY
LEU
8
11
1.45
8
A
B
H
O
ASN
GLY
21
23
1.47
8
B
B
O
H
GLU
LEU
13
17
1.51
9
A
B
H
O
ASN
GLY
21
23
1.51
9
B
B
O
H
GLY
GLY
20
23
1.52
9
B
B
O
H
GLU
LEU
13
17
1.53
9
B
B
O
H
GLY
LEU
8
11
1.54
10
B
B
O
H
GLY
LEU
8
11
1.48
10
A
B
H
O
ASN
GLY
21
23
1.49
10
B
B
O
H
GLU
LEU
13
17
1.55
11
A
B
H
O
ASN
GLY
21
23
1.47
11
B
B
O
H
ALA
VAL
14
18
1.57
12
B
B
O
H
GLY
LEU
8
11
1.56
12
B
B
O
H
GLU
LEU
13
17
1.56
13
A
B
H
O
ASN
GLY
21
23
1.47
13
B
B
O
H
GLY
LEU
8
11
1.47
13
B
B
O
H
GLU
LEU
13
17
1.48
13
B
B
O
H
CYS
GLU
19
21
1.56
13
A
A
O
H
SER
GLN
12
15
1.58
14
A
B
H
O
ASN
GLY
21
23
1.48
14
B
B
O
H
GLU
LEU
13
17
1.53
15
A
B
H
O
ASN
GLY
21
23
1.47
15
B
B
O
H
GLY
LEU
8
11
1.51
15
B
B
O
H
GLU
LEU
13
17
1.53
1
B
ARG
22
0.312
SIDE CHAIN
2
B
ARG
22
0.213
SIDE CHAIN
4
B
ARG
22
0.272
SIDE CHAIN
5
B
ARG
22
0.314
SIDE CHAIN
6
B
ARG
22
0.295
SIDE CHAIN
7
B
ARG
22
0.236
SIDE CHAIN
8
B
ARG
22
0.206
SIDE CHAIN
9
B
ARG
22
0.296
SIDE CHAIN
10
B
ARG
22
0.239
SIDE CHAIN
11
B
ARG
22
0.312
SIDE CHAIN
12
B
ARG
22
0.311
SIDE CHAIN
13
B
ARG
22
0.141
SIDE CHAIN
14
B
ARG
22
0.174
SIDE CHAIN
15
B
ARG
22
0.237
SIDE CHAIN
1
A
LEU
13
-38.53
-28.43
1
B
CYS
19
-116.03
-78.95
1
B
LYS
28
61.48
116.73
1
B
PRO
29
-77.42
-77.53
2
A
LEU
13
-28.80
-40.06
2
B
VAL
2
-86.11
-112.13
2
B
CYS
7
-120.35
-80.64
2
B
CYS
19
-116.97
-77.94
2
B
LYS
28
170.66
79.71
3
A
GLN
5
-102.86
-87.37
3
A
THR
8
-89.79
30.08
3
A
SER
9
164.35
-167.62
3
B
VAL
2
-97.39
50.88
3
B
ASN
3
-50.21
84.05
3
B
CYS
19
-94.52
-61.10
3
B
GLU
21
-65.40
87.77
3
B
ARG
22
174.62
-35.39
3
B
LYS
28
-163.84
89.37
4
A
GLN
5
-101.07
-102.74
4
A
SER
9
-120.26
-157.82
4
A
LEU
13
-23.60
-56.97
4
B
ASN
3
40.53
24.40
4
B
CYS
19
-108.45
-73.91
5
A
LEU
13
-27.04
-44.92
5
B
ASN
3
39.52
47.12
5
B
CYS
19
-131.63
-58.62
5
B
PHE
24
-171.46
124.08
6
A
GLN
5
-95.53
-75.94
6
A
SER
9
-146.15
-156.50
6
B
VAL
2
-100.25
-88.85
6
B
ASN
3
-111.01
53.40
6
B
LEU
6
-177.36
115.43
6
B
GLU
13
-91.73
-60.93
6
B
CYS
19
-130.78
-73.95
7
A
VAL
3
-49.91
-16.99
7
A
GLN
5
-99.84
-76.63
7
A
SER
9
-118.89
-167.61
7
B
VAL
2
-60.26
-103.50
7
B
LEU
6
-119.06
-163.37
7
B
CYS
7
-165.90
-86.68
7
B
CYS
19
-128.47
-75.75
7
B
LYS
28
-178.27
97.55
7
B
PRO
29
-78.49
-160.79
8
A
GLN
5
-97.16
-65.21
8
A
CYS
7
-76.60
-85.36
8
A
SER
9
-128.27
-167.88
8
A
LEU
13
-39.23
-27.43
8
B
VAL
2
-100.36
53.21
8
B
ASN
3
-53.22
92.16
8
B
CYS
7
-117.55
-98.51
8
B
CYS
19
-130.31
-76.62
8
B
TYR
26
-114.09
72.86
8
B
LYS
28
-154.21
52.31
9
A
CYS
7
-93.65
-61.98
9
B
CYS
7
-126.62
-88.86
9
B
CYS
19
-112.86
-77.53
9
B
PRO
29
-78.39
-167.12
10
A
THR
8
-68.19
-73.40
10
A
LEU
13
-30.70
-34.73
10
B
ASN
3
-26.99
87.75
10
B
CYS
7
-119.28
-79.69
10
B
CYS
19
-107.72
-75.76
10
B
PHE
25
-100.41
-89.62
10
B
TYR
26
99.90
73.44
10
B
LYS
28
177.51
106.88
11
A
SER
9
-109.79
-159.03
11
B
VAL
2
-43.81
96.04
11
B
ASN
3
-95.47
49.90
11
B
LEU
6
-172.68
99.86
11
B
CYS
19
-111.35
-76.40
11
B
LYS
28
-163.08
60.62
12
A
GLN
5
-101.14
-65.75
12
A
LEU
13
-37.66
-28.99
12
B
ASN
3
-47.19
94.70
12
B
VAL
18
-102.33
-62.05
12
B
PHE
25
-100.77
-90.41
12
B
TYR
26
103.73
84.97
12
B
THR
27
-60.41
-179.23
13
A
GLN
5
-105.94
-79.56
13
A
SER
9
-107.22
-163.73
13
A
LEU
13
-37.07
-28.44
13
B
CYS
7
-114.07
-84.96
13
B
CYS
19
-111.30
-75.62
13
B
LYS
28
-173.75
74.61
14
A
GLN
5
-103.30
-75.80
14
A
SER
9
-121.08
-164.03
14
A
LEU
13
-32.86
-32.34
14
B
ASN
3
58.82
17.59
14
B
CYS
19
-129.21
-72.71
14
B
LYS
28
74.94
69.39
15
B
ASN
3
-56.04
83.39
15
B
CYS
7
-130.17
-83.66
15
B
CYS
19
-112.17
-78.24
15
B
PHE
25
-100.47
-81.77
15
B
TYR
26
89.67
92.84
NMR STRUCTURE OF HUMAN INSULIN MUTANT HIS-B10-ASP, VAL-B12-ABA, PRO-B28-LYS, LYS-B29-PRO, 15 STRUCTURES
1
N
N
2
N
N
A
SER
12
A
SER
12
HELX_P
A
GLU
17
A
GLU
17
1
1
6
B
CYS
7
B
CYS
7
HELX_P
B
CYS
19
B
CYS
19
1
2
13
disulf
2.013
A
CYS
6
A
SG
CYS
6
1_555
A
CYS
11
A
SG
CYS
11
1_555
disulf
2.020
A
CYS
7
A
SG
CYS
7
1_555
B
CYS
7
B
SG
CYS
7
1_555
disulf
2.019
A
CYS
20
A
SG
CYS
20
1_555
B
CYS
19
B
SG
CYS
19
1_555
covale
1.303
both
B
LEU
11
B
C
LEU
11
1_555
B
ABA
12
B
N
ABA
12
1_555
covale
1.309
both
B
ABA
12
B
C
ABA
12
1_555
B
GLU
13
B
N
GLU
13
1_555
HORMONE/GROWTH FACTOR
Aba-B12-DKP-insulin, protein unfolding, insulin receptor, receptor binding, HORMONE-GROWTH FACTOR COMPLEX
INS_HUMAN
UNP
1
1
P01308
GIVEQCCTSICSLYQLENYCN
INS_HUMAN
UNP
2
25
P01308
FVNQHLCGSHLVEALYLVCGERGFFYTPKT
1
21
1T1Q
1
21
P01308
A
1
1
21
25
54
1T1Q
1
30
P01308
B
2
1
30
2
HIS
engineered mutation
ASP
10
1T1Q
B
P01308
UNP
34
10
2
VAL
engineered mutation
ABA
12
1T1Q
B
P01308
UNP
36
12
2
PRO
engineered mutation
LYS
28
1T1Q
B
P01308
UNP
52
28
2
LYS
engineered mutation
PRO
29
1T1Q
B
P01308
UNP
53
29